Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PDE8B | O95263 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3434909 | 0.98 | HSD17B10 (0.48) | HSD17B10HPGDEPHX1CHRM2CHRM1 | |
| SCHEMBL1427524 | 0.98 | HSD17B10 (0.48) | HSD17B10HPGDEPHX1CHRM2CHRM1 | |
| SCHEMBL12486284 | 0.98 | HSD17B10 (0.48) | HSD17B10HPGDEPHX1CHRM2CHRM1 | |
| SCHEMBL29126181 | 0.97 | HPGD (0.50) | HSD17B10HPGDEPHX1CHRM2CHRM1 | |
| SCHEMBL31459726 | 0.97 | HPGD (0.50) | HSD17B10HPGDEPHX1CHRM2CHRM1 | |
| Methane SCHEMBL667082 | 0.95 | HSD17B10 (0.51) | HSD17B10HPGDEPHX1CHRM2CHRM1 | |
| SCHEMBL559852 | 0.93 | HSD17B10 (0.52) | HSD17B10HPGDEPHX1CHRM2CHRM1 | |
| SCHEMBL1115598 | 0.93 | HSD17B10 (0.52) | HSD17B10HPGDEPHX1CHRM2CHRM1 | |
| SCHEMBL1010839 | 0.93 | HSD17B10 (0.52) | HSD17B10HPGDEPHX1CHRM2CHRM1 | |
| SCHEMBL1550543 | 0.93 | HSD17B10 (0.52) | HSD17B10HPGDEPHX1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192673-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192673-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, NPY1R | HSD17B10 961/4885HPGD 922/4885EPHX1 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.